These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16538101)

  • 61. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.
    Witthoeft T; Fuchs M; Ludwig D
    World J Gastroenterol; 2007 Jan; 13(4):579-84. PubMed ID: 17278224
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin.
    Parikh M; Singh A; Sood G
    J Viral Hepat; 2011 Apr; 18(4):e99-103. PubMed ID: 20950407
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.
    Mangia A; Santoro R; Piattelli M; Leandro G; Minerva N; Annese M; Bacca D; Spirito F; Carretta V; Ventrella F; Cela M; Andriulli A
    J Hepatol; 2002 Jul; 37(1):109-16. PubMed ID: 12076869
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.
    Toyoda H; Kumada T; Tada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2012 Jan; 84(1):61-70. PubMed ID: 22095536
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Therapeutic behaviour for a HCV+ patient].
    Buffet C
    Presse Med; 2004 Apr; 33(7):497-8. PubMed ID: 15105775
    [No Abstract]   [Full Text] [Related]  

  • 68. You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.
    Pearlman BL; Lim TH
    Dig Dis Sci; 2014 Aug; 59(8):1681-3. PubMed ID: 25002310
    [No Abstract]   [Full Text] [Related]  

  • 69. Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapy.
    Campo DS; Skums P; Dimitrova Z; Vaughan G; Forbi JC; Teo CG; Khudyakov Y; Lau DT
    Clin Pharmacol Ther; 2014 Jun; 95(6):627-35. PubMed ID: 24488144
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
    Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
    Mangia A; Mottola L; Piazzolla V
    Clin Infect Dis; 2013 May; 56(9):1294-300. PubMed ID: 23271787
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Individualization of antiviral treatment regimens for chronic hepatitis C.
    Paulon E; Naoumov NV
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):321-5. PubMed ID: 16538101
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Oct; 84(10):1593-9. PubMed ID: 22930507
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
    McHutchison JG; Manns M; Patel K; Poynard T; Lindsay KL; Trepo C; Dienstag J; Lee WM; Mak C; Garaud JJ; Albrecht JK;
    Gastroenterology; 2002 Oct; 123(4):1061-9. PubMed ID: 12360468
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 76. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
    Kondo C; Atsukawa M; Tsubota A; Itokawa N; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Sakamoto C
    J Viral Hepat; 2012 Sep; 19(9):615-22. PubMed ID: 22863265
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.